InVivoMAb anti-human CD47
The B6H12 monoclonal antibody reacts with human CD47 otherwise known as integrin-associated protein (IAP), and neurophilin. CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells. CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. Furthermore, it plays a key role in immune and angiogenic responses. CD47 is a receptor for thrombospondin-1 (TSP-1), a secreted glycoprotein that plays a role in vascular development and angiogenesis. CD47 Is has been found to be overexpressed in many different tumor cells. Because of this, anti-CD47 monoclonal antibodies have been proposed and studied as a therapeutic treatment for human cancers. The B6H12 antibody has been shown to neutralize CD47 and inhibit the growth of hepatocellular carcinoma cells in vitro.
|Recomended Isotype Control(s)||InVivoMAb mouse IgG1 isotype control, unknown specificity|
|Recommended InVivoPure Dilution Buffer||InVivoPure pH 7.0 Dilution Buffer|
Intact CD47 purified from placenta
0.2 μM filtered
Purified from tissue culture supernatant in an animal free facility
Undiluted at 4°C in the dark